The 4th TPD Summit Europe returns as Europe’s definitive meeting for uniting Targeted Protein Degradation professionals within Europe and across the globe to explore novel degrader development with new E3 ligase/ligand discovery, overcome safety concerns in PROTACs, and rationally discover molecular glues to deliver clinically approved degraders to high-value targets and patients in need.

Across 3-days, our speaker faculty of 35+ world-class TPD specialists will cover end-to-end degrader drug development from novel hit finding, validation, and lead optimisation in our discovery track, to assessing DMPK profiles, measuring efficacy and dose escalation for clinical candidates in our preclinical/clinical track.

Join a community of 110+ protein degradation professionals at the interface of academia and industry and form key global connections to deliver a new generation of degraders that will transform the lives of patients worldwide.


Drug Developer Pricing – Conference Only: GBP 2599.00,
Drug Developer Pricing – Conference + Workshop Day : GBP 3697.00,
Academic and Research Institute Pricing – Conference Only : GBP 2199.00,
Academic and Research Institute Pricing – Conference + Workshop Day : GBP 3097.00,
Service Provider Pricing – Conference Only: GBP 3099.00,
Service Provider Pricing – Conference + Workshop Day : GBP 4397.00

Speakers: Chris Tame, Vice President and Head of Drug Discovery, Celeris Therapeutics, David Shorthouse, Lecturer, University College London, School of Pharmacy, Diogo Feleciano, Co-Founder and Chief Operating Officer, Booster Therapeutics, Edward Tate, Professor and GSK Chair in Chemical Biology, Imperial College London, Enrica Colasurdo, Principal Scientist, Sibylla Biotech, Frank Dekker, Assistant Professor, University of Groningen, Fred Derheimer, Associate Research Fellow, Pfizer, Graham Simpson, Senior Vice President Drug Discovery, Dunad Therapeutics, György M. Keseru, Director, Drug Innovation Centre, Research Centre for Natural Sciences, Hungary, Ivan Dikic, Professor and Steering Board Member, PROXIDRUGS, John Caldwell, Senior Staff Scientist, The Institute of Cancer Research, Kaat Durinck, Professor, Ghent University, Kirsten McAulay, Team Leader, Centre for Target Protein Degradation, University of Dundee, Kirti Sharma, Senior Director Proteomics, Kymera Therapeutics, Laura Gasparini, Tau Pathobiology and Area Leader, AbbVie, Marcus Hartmann, Group Leader, Max Planck Institute for Biology Tübingen and University of Tübingen, Markus Queisser, Director – Scientific Leader, GlaxoSmithKline, Markus Schade, Principal Scientist, AstraZeneca, Martin Schwalm, Structural Genomics Consortium Scientist, Goethe University Frankfurt, Matthew Wakeham, Team Leader, BASF, Merve Mutlu-Koch, Discovery Fellow, Novartis Institutes for BioMedical Research (NIBR), Oliver Hsia, Post-Doctoral Researcher, University of Dundee, Centre for Targeted Protein Degradation, Paula O’Connor, Senior Vice President, Head of Clinical Development, Nurix Therapeutics, Pearl Huang, Chief Executive Officer, Dunad Therapeutics, Ralph Tiedt, Vice President Oncology, Monte Rosa Therapeutics, Rhiannon David, Director, Microphysiological Systems, AstraZeneca, Richard Boyce, Senior Vice President Drug Discovery, PhoreMost, Sam Lievens, Director Biology, Orionis Biosciences, Shawn Schiller, Director Medicinal Chemistry, Foghorn Therapeutics, Shyra Gardai, Chief Scientific Officer, EpiBiologics, Simon Glerup, Chief Scientific Officer, Draupnir Bio, Stefan Knapp, Professor of Pharmaceutical Chemistry, SGC Frankfurt, Swen Hoelder, Professor and Interim Director, The Institute of Cancer Research, Tauseef Butt, Chief Executive Officer, Progenra, Victor Guallar, ICREA Research Professor, Barcelona Supercomputing Center